Item 1 - Translational research design
The preclinical activity of our research unit is based on our experience of neurovascular coupling, that is to say the relationship between local neuronal activity and changes in cerebral blood flow.
It has been studied at the cellular level by electrophysiology, at the organ level by vasomotion tests and in vivo by pharmacological approaches. It has made it possible to understand post-ischemic damage and explore neuroprotection strategies. This integrated approach to brain injury has been shown to be consistent with more recent vascular hypotheses in the context of a growing number of neurodegenerative diseases. This complexity feeds our transnosographic approach initiated since the previous wave of evaluation, and offers an asset for long-term intervention in the natural history of these chronic diseases.
This encourages us to consider the natural history of brain diseases from the subclinical stage, where the brain predisposes to disease in interaction with its environment, to the post-diagnostic stage, where severity and complications threaten survival and patient autonomy.
Our unit has therefore mobilized its preclinical assets to define or enrich the natural history of neurovascular and neurodegenerative diseases at each stage, in order to generate data more translatable into clinical practice, and to initiate new clinical studies.
For example, in the field of intracerebral hemorrhages (syndrome stage), the preclinical studies by Puy L, et al. (PMID: 33971034, 35465695, 35844211, 36779341) led to the COPITCH and DARLENE clinical studies. In the field of Parkinson's disease (syndromic stage), preclinical studies (PMID: 24251381, PMID: 27189756, PMID: 29287521, PMID: 32205254, PMID: 28363801) have led to FAIRPARK-I, FAIRPARK-II, FAIRALS- II, DIVE- I do clinical trials.
